Asia Australia Central America North America South America Eastern Europe Western Europe Middle East
Product Description
TAGRIX is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)